JACC. Case reports · 2026
Recurrent In-Stent Restenosis and Accelerated Neoatherosclerosis in a Middle-Aged Woman With High Inflammatory Burden.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Wenhao, Han Wenqi, Wang Zhenyu
Аннотация
BACKGROUND: Recurrent in-stent restenosis (ISR) driven by accelerated neoatherosclerosis and high residual inflammatory risk remains a formidable clinical challenge.
CASE SUMMARY: A 50-year-old noncompliant, obese, diabetic woman presented with recurrent multivessel ISR. Intravascular ultrasound confirmed intrastent thin-cap fibroatheromas. Despite multiple drug-coated balloon interventions, intensive lipid-lowering via inclisiran, and glycemic control with tirzepatide, she suffered relentless ISR driven by highly elevated interleukin-6. She received advanced anti-inflammatory therapies and was referred for bypass surgery.
DISCUSSION: Literature highlights that targeting upstream inflammation is critical when standard therapies fail to halt malignant neoatherosclerosis. This case interests readers by demonstrating compliance optimization via long-acting agents and navigating advanced anti-inflammatory pathways (colchicine escalation, canakinumab) for refractory ISR.
TAKE-HOME MESSAGES: Biomarkers like interleukin-6 must be evaluated in refractory ISR; persistent residual inflammation warrants advanced anti-inflammatory therapies or early surgical revascularization.
CASE SUMMARY: A 50-year-old noncompliant, obese, diabetic woman presented with recurrent multivessel ISR. Intravascular ultrasound confirmed intrastent thin-cap fibroatheromas. Despite multiple drug-coated balloon interventions, intensive lipid-lowering via inclisiran, and glycemic control with tirzepatide, she suffered relentless ISR driven by highly elevated interleukin-6. She received advanced anti-inflammatory therapies and was referred for bypass surgery.
DISCUSSION: Literature highlights that targeting upstream inflammation is critical when standard therapies fail to halt malignant neoatherosclerosis. This case interests readers by demonstrating compliance optimization via long-acting agents and navigating advanced anti-inflammatory pathways (colchicine escalation, canakinumab) for refractory ISR.
TAKE-HOME MESSAGES: Biomarkers like interleukin-6 must be evaluated in refractory ISR; persistent residual inflammation warrants advanced anti-inflammatory therapies or early surgical revascularization.